Clinical Trials open to enrollment

CARE Study – “Epidemiology of Triple Negative Breast CAncer in Italy: ChaRacterization of Patients and TrEatment Patterns”

Catanzaro – AOU Renato Dulbecco – Presidio Mater Domini
Principal Investigator: Prof. Pierfrancesco Tassone
For information about enrollment, contact: clinicaltrials.oncology@unicz.it (Tel: +39 0961-3647921)

 

DYNASTY-Breast02 – “A Study of DB-1303/BNT323 vs Investigator’s Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer”

This study evaluates the role of the DB-1303/BNT323 molecule in hormone receptor-positive, HER2-low breast cancer (HER2 immunohistochemistry 1+ or 2+ with negative FISH) in patients who have progressed after two prior lines of hormone therapy or within six months of combined hormone therapy with a CDK4/6 inhibitor. It compares DB-1303/BNT323 to single-agent chemotherapy (capecitabine, paclitaxel, or nab-paclitaxel).
Catanzaro – AOU Renato Dulbecco – Presidio Mater Domini
Principal Investigator: Prof. Pierfrancesco Tassone
For information about enrollment, contact: clinicaltrials.oncology@unicz.it (Tel: +39 0961-3647921)

 

GIM 14 – BIO-META – A Retrospective-prospective observational study to evaluate medical treatments (chemotherapy, hormonal therapy and biological therapies) in metastatic breast cancer patients according to biologic subtype and line of
treatment

Catanzaro – AOU Renato Dulbecco – Presidio Mater Domini
Principal Investigator: Doc. Nicoletta Staropoli
For information about enrollment, contact: clinicaltrials.oncology@unicz.it (Tel: +39 0961-3647921)